MCID: CRB059
MIFTS: 32

Cerebellar Degeneration malady

Categories: Rare diseases, Neuronal diseases, Metabolic diseases

Aliases & Classifications for Cerebellar Degeneration

About this section

Aliases & Descriptions for Cerebellar Degeneration:

Name: Cerebellar Degeneration 48 49 50 68

Classifications:



Summaries for Cerebellar Degeneration

About this section
NIH Rare Diseases:48 Cerebellar degeneration refers to the deterioration of neurons (nerve cells) in the cerebellum (the area of the brain that controls muscle coordination and balance). Conditions that cause cerebellar degeneration may also affect other areas of the central nervous system, such as the spinal cord, the cerebral cortex (the thin layer of cells covering the brain), and the brain stem. Signs and symptoms of cerebellar degeneration may include a wide-based, uncoordinated walk; a back and forth tremor in the trunk of the body; uncoordinated movements of the arms and legs; slow and slurred speech; and nystagmus. Cerebellar degeneration can be caused by a variety of factors including inherited gene changes (mutations), chronic alcohol abuse, and paraneoplastic disorders. Treatment for cerebellar degeneration varies depending on the underlying cause. Last updated: 12/14/2014

MalaCards based summary: Cerebellar Degeneration is related to hereditary spastic paraplegia and paraneoplastic cerebellar degeneration. An important gene associated with Cerebellar Degeneration is CDR1 (Cerebellar Degeneration Related Protein 1). Affiliated tissues include brain, cortex and spinal cord, and related mouse phenotype Increased shRNA abundance (Z-score > 2).

NINDS:49 Cerebellar degeneration is a process in which neurons in the cerebellum - the area of the brain that controls coordination and balance - deteriorate and die. Diseases that cause cerebellar degeneration can also involve other areas of the central nervous system,including the spinal cord, medulla oblongata, cerebral cortex, and brain stem. Cerebellar degeneration may be the result of inherited genetic mutations that alter the normal production of specific proteins that are necessary for the survival of neurons.

Related Diseases for Cerebellar Degeneration

About this section

Diseases in the Cerebellar Degeneration family:

Primary Cerebellar Degeneration Subacute Cerebellar Degeneration

Diseases related to Cerebellar Degeneration via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 117)
idRelated DiseaseScoreTop Affiliating Genes
1hereditary spastic paraplegia29.2ATXN2, CACNA1A
2paraneoplastic cerebellar degeneration12.3
3subacute cerebellar degeneration12.1
4primary cerebellar degeneration12.0
5ichthyosis, hepatosplenomegaly, and cerebellar degeneration12.0
6paraneoplastic syndromes11.1
7ataxia-telangiectasia-like disorder11.0
8infantile cerebellar-retinal degeneration10.8
9spinocerebellar ataxia 210.8
10dykes markes harper syndrome10.8
11menkes disease10.7
12familial hemiplegic migraine10.7
13apraxia10.2CDR1, CDR2
14neuronitis10.2
15lymphoma10.1
16adenocarcinoma10.1
17ataxia10.1
18lambert-eaton myasthenic syndrome10.1
19breast cancer10.0
20ovarian cancer10.0
21lung cancer10.0
22prostatitis9.9
23tremor9.9
24celiac disease 139.9ATXN2, CACNA1A
25hodgkin lymphoma9.8
26encephalitis9.8
27limbic encephalitis9.8
28okt4 epitope deficiency9.8ATXN2, CACNA1A
29dracunculiasis9.8ATXN2, CACNA1A
30lambert syndrome9.8
31neuroleptic malignant syndrome9.8
32prostate adenocarcinoma9.8
33neuropathy9.8
34mental retardation, autosomal recessive 329.7ATXN2, CACNA1A
35paraomphalocele9.7CACNA1A, CDR1, CDR2
36ataxia-telangiectasia9.7
37endometrial cancer9.7
38b-cell lymphomas9.7
39diffuse large b-cell lymphoma9.7
40severe combined immunodeficiency9.7
41dementia9.7
42diarrhea9.7
43hypogonadism9.7
44neuroaxonal dystrophy9.7
45cerebritis9.7
46retinitis9.7
47fallopian tube adenocarcinoma9.7
48merkel cell carcinoma9.7
49paraplegia9.7
50spasticity9.7

Graphical network of the top 20 diseases related to Cerebellar Degeneration:



Diseases related to cerebellar degeneration

Symptoms & Phenotypes for Cerebellar Degeneration

About this section

GenomeRNAi Phenotypes related to Cerebellar Degeneration according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00366-A-359.3ACO2, ATM

Drugs & Therapeutics for Cerebellar Degeneration

About this section

Drugs for Cerebellar Degeneration (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 130)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
BupropionapprovedPhase 431934841-39-9, 34911-55-2444
Synonyms:
( -)-2-(tert-Butylamino)-3'-chloropropiophenone
( -)-2-(tert-Butylamino)-3'-chlorpropiophenon
(+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
(+-)-Bupropion
.alpha.-(tert-Butylamino)-m-chloropropiophenone
1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one
2-(Tert-Butylamino)-3'-chloropropiophenone
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
34841-36-6 (hydrochloride)
34841-39-9
34911-55-2
AB00053756
AC-197
AC1L198Y
AMFEBUTAMONE HCl
Amfebutamon
Amfebutamona
Amfebutamona [INN-Spanish]
Amfebutamone
Amfebutamonum
Amfebutamonum [INN-Latin]
BPBio1_000042
BRD-A05186015-003-05-7
BRN 2101062
BSPBio_000038
BSPBio_002247
Bupropion (INN)
Bupropion (Old RN)
Bupropion (USAN)
Bupropion Hcl
Bupropion SR
Bupropion [INN:BAN]
Bupropion hydrocloride
C06860
CHEBI:3219
CHEMBL894
CID444
CPD000472526
D07591
DB01156
DivK1c_007050
Elont
 
HMS2051G10
HMS2089G14
Jsp006301
KBio1_001994
KBio2_002143
KBio2_004711
KBio2_007279
KBio3_001467
KBioGR_001168
KBioSS_002143
L000725
LS-122817
Lopac0_000166
MLS001424015
MolPort-003-845-432
NCGC00015122-06
NCGC00089751-02
NCI60_002714
NSC315851
Prestwick0_000249
Prestwick1_000249
Prestwick2_000249
Prestwick3_000249
SAM001246699
SMR000472526
SPBio_001817
SPBio_002257
SpecPlus_000954
Spectrum2_001659
Spectrum3_000644
Spectrum4_000614
Spectrum5_001406
Spectrum_001663
TL8002604
UNII-01ZG3TPX31
Wellbatrin
Wellbutrin
Wellbutrin SR
Wellbutrin XL
Zyban
alpha-(tert-butylamino)-m-chloropropiophenone
amfebutamonum
bupropion
2
CitalopramapprovedPhase 450359729-33-82771
Synonyms:
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
Bonitrile
C07572
C20H21FN2O
CHEBI:3723
CHEMBL549
CID2771
CPD000465669
Celapram
Celexa
Celius
Ciazil
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
Citalopram (USP/INN)
Citalopram Hydrobromide
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
 
Citol
Citopam
Citox
Citrol
Cytalopram
D07704
DB00215
Dalsan
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
LS-84327
Lopac0_000258
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
ST069372
STL058639
Seropram
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
[3H]Citalopram
citalopram
3
DopamineapprovedPhase 4, Phase 1, Phase 2375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
4ParasympatholyticsPhase 41050
5Neurotransmitter AgentsPhase 4, Phase 2, Phase 317734
6Neurotransmitter Uptake InhibitorsPhase 43464
7
SerotoninPhase 4356650-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
8Antidepressive AgentsPhase 4, Phase 2, Phase 3, Phase 12666
9Serotonin Uptake InhibitorsPhase 41570
10Serotonin AgentsPhase 43102
11Muscarinic AntagonistsPhase 41134
12Peripheral Nervous System AgentsPhase 4, Phase 1, Phase 2, Early Phase 122776
13Psychotropic DrugsPhase 4, Phase 2, Phase 3, Phase 16279
14Autonomic AgentsPhase 4, Early Phase 19774
15Antidepressive Agents, Second-GenerationPhase 41287
16Dopamine Uptake InhibitorsPhase 41305
17Cholinergic AgentsPhase 4, Phase 2, Phase 33846
18Antiparkinson AgentsPhase 41527
19Cytochrome P-450 Enzyme InhibitorsPhase 43822
20Cytochrome P-450 CYP2D6 InhibitorsPhase 4716
21Dopamine AgentsPhase 4, Phase 1, Phase 23759
22Cholinergic AntagonistsPhase 41658
23Idebenoneapproved, investigationalPhase 3, Phase 2, Phase 12158186-27-9
24
Riluzoleapproved, investigationalPhase 2, Phase 3631744-22-55070
Synonyms:
1744-22-5
2-Amino-6-(trifluoromethoxy)-benzothiazole
2-Amino-6-(trifluoromethoxy)benzothiazole
2-Amino-6-trifluoro- methoxybenzothiazole
2-amino-6-(trifluoromethoxy)-1,3-benzothiazole
2-amino-6-(trifluoromethoxy)benzo[d]thiazole
2-amino-6-(trifluoromethoxyl)benzothiazole
2-amino-6-trifluoromethoxybenzothiazole
6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
6-(trifluoromethoxy)benzo[d]thiazol-2-amine
6-Trifluoromethoxy-benzothiazol-2-ylamine
6-trifluoromethoxybenzothiazole-2-yl-amine
AC-730
AC1L1JJL
AC1Q530H
AKOS000265071
ALBB-006046
Amino-2 trifluoromethoxy-6 benzothiazole
Amino-2 trifluoromethoxy-6 benzothiazole [French]
BB_SC-4839
BF-37
BIDD:GT0055
BPBio1_000037
BPBio1_000837
BRD-K21283037-001-02-5
BRD-K21283037-003-03-9
BSPBio_000033
Bio1_000416
Bio1_000905
Bio1_001394
Biomol-NT_000245
C07937
C8H5F3N2OS
CHEMBL744
CID5070
D00775
DB00740
EU-0101064
FT-0082997
HMS1773G08
HMS2089O19
HMS2094G07
I01-2084
LS-40688
 
Lopac-R-116
Lopac0_001064
MLS000069369
MolPort-000-151-262
NCGC00015882-01
NCGC00015882-02
NCGC00015882-03
NCGC00015882-07
NCGC00015882-11
NCGC00023141-02
NCGC00023141-04
NCGC00023141-05
NCGC00023141-06
PK-26124
PK-26124, RP-54274, Rilutek, Riluzole
Prestwick-03A08
Prestwick0_000167
Prestwick1_000167
Prestwick2_000167
Prestwick3_000167
R-116
R116_SIGMA
RP 54274
RP-54274
Rilutek
Rilutek (TN)
Riluzol
Riluzol [INN-Spanish]
Riluzole
Riluzole (JAN/USAN/INN)
Riluzole HCl
Riluzole [USAN:INN]
Riluzolum
Riluzolum [INN-Latin]
S1614_Selleck
SMR000058231
SPBio_000599
SPBio_001954
STK503686
Spectrum2_000550
Tocris-0768
UNII-7LJ087RS6F
ZERO/001785
ZINC00006481
riluzole
25
Pioglitazoneapproved, investigationalPhase 3435111025-46-84829
Synonyms:
(+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione
(+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione
105355-27-9
111025-46-8
198077-89-3
2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione
5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione
5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione
5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione
AB1004597
AC-1021
AC1L1J1Q
AD 4833
AD-4833
Actos
Actos (TN)
Actost
BRD-A48430263-003-02-4
BSPBio_002723
C07675
C19H20N2O3S
CHEBI:8228
CHEMBL595
CID4829
D08378
DB01132
Duetact
Glustin
HMS2089H14
HS-0047
 
HSDB 7322
I06-0089
KBio2_002103
KBio2_004671
KBio2_007239
KBio3_001943
KBioGR_001619
KBioSS_002103
LS-151327
MolPort-002-508-211
NCGC00163128-01
NCGC00163128-02
Pioglitazona
Pioglitazona [INN-Spanish]
Pioglitazone
Pioglitazone HCl
Pioglitazone Hydrochloride
Pioglitazone [BAN:INN]
Pioglitazone [Ban:Inn]
Pioglitazone [INN:BAN]
Pioglitazonum
Pioglitazonum [INN-Latin]
SPBio_001897
Spectrum2_001679
Spectrum3_001002
Spectrum4_001130
Spectrum5_001480
Spectrum5_002067
Spectrum_001623
U 72107
U 72107A
U-72107
U72,107A
UNII-X4OV71U42S
Zactos
nchembio790-comp10
pioglitazone (INN)
pioglitazone HCl
26
Vareniclineapproved, investigationalPhase 2, Phase 3269249296-44-45310966
Synonyms:
249296-44-4
7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)(3)benzazepine
7,8,9,10-tetrahydro-6h-6,10-methanoazepino[4,5-g]quinoxaline
AC1L55H0
AC1Q4W6H
AKOS005145561
AR-1H2911
CHEBI:430452
CHEMBL1396
CID170361
CP 526555
 
CP-526,555
Champix
Chantix
D08669
HSDB 7591
I14-1963
LS-187375
UNII-W6HS99O8ZO
Varenicline
Varenicline (INN)
Varenicline tartrate
varenicline
27Anti-Infective AgentsPhase 3, Phase 221402
28interferonsPhase 3, Phase 22137
29Interferon-gammaPhase 3, Phase 2145
30Antiviral AgentsPhase 3, Phase 29732
31AntioxidantsPhase 3, Phase 2, Phase 12928
32Nicotinic AgonistsPhase 2, Phase 3902
33Tranquilizing AgentsPhase 2, Phase 3, Phase 14164
34Hypoglycemic AgentsPhase 35733
35UbiquinonePhase 3, Phase 2, Phase 1139
36Trace ElementsPhase 3, Phase 2, Phase 15802
37MicronutrientsPhase 3, Phase 2, Phase 15802
38Central Nervous System DepressantsPhase 2, Phase 3, Phase 112806
39Thyrotropin-Releasing HormonePhase 3, Phase 214
40AnticonvulsantsPhase 2, Phase 32620
41Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 2, Early Phase 112767
42HormonesPhase 3, Phase 2, Early Phase 113979
43calcitoninPhase 3, Phase 2103
44Lithium carbonatePhase 2, Phase 3, Phase 1232554-13-2
45Excitatory Amino Acid AntagonistsPhase 2, Phase 31282
46Hormone AntagonistsPhase 3, Phase 2, Early Phase 112778
47VaccinesPhase 36428
48Excitatory Amino AcidsPhase 2, Phase 31297
49Heptavalent Pneumococcal Conjugate VaccinePhase 3454
50Antimanic AgentsPhase 2, Phase 3, Phase 1790

Interventional clinical trials:

(show top 50)    (show all 103)
idNameStatusNCT IDPhase
1An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich AtaxiaCompletedNCT01716221Phase 4
2An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)CompletedNCT01970111Phase 3
3A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)CompletedNCT01970098Phase 3
4Efficacy of Riluzole in Hereditary Cerebellar AtaxiaCompletedNCT01104649Phase 2, Phase 3
5Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT)CompletedNCT00656409Phase 3
6A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)CompletedNCT01970124Phase 3
7A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)CompletedNCT01970137Phase 3
8Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3CompletedNCT01096082Phase 2, Phase 3
9Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's AtaxiaCompletedNCT02415127Phase 3
10Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI)CompletedNCT01303406Phase 3
11Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension)CompletedNCT00993967Phase 3
12A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) PatientsCompletedNCT00905268Phase 3
13Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of ConceptCompletedNCT00811681Phase 3
14Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia PatientsCompletedNCT00697073Phase 3
15Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's AtaxiaCompletedNCT00537680Phase 3
16An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)RecruitingNCT02889302Phase 3
17Trial in Adult Subjects With Spinocerebellar AtaxiaRecruitingNCT02960893Phase 2, Phase 3
18Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation in Friedreich's Ataxia StudyActive, not recruitingNCT02593773Phase 3
19STEADFAST Long-Term Safety ExtensionEnrolling by invitationNCT02797080Phase 3
20Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's AtaxiaTerminatedNCT00803868Phase 2, Phase 3
21A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells TransplantationUnknown statusNCT01489267Phase 2
22Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary AtaxiaUnknown statusNCT01360164Phase 1, Phase 2
23The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph DiseaseUnknown statusNCT02039206Phase 2
24A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA PatientsUnknown statusNCT02035020Phase 2
25High-Dose Intravenous Immunoglobulin to Treat Cerebellar DegenerationCompletedNCT00034242Phase 2
26Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3CompletedNCT00992771Phase 2
27A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)CompletedNCT01503944Phase 1, Phase 2
28Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar AtaxiaCompletedNCT00202397Phase 2
29A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)CompletedNCT01004016Phase 2
30Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)CompletedNCT00863538Phase 2
31A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)CompletedNCT01384435Phase 2
32Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar AtaxiaCompletedNCT01350440Phase 2
33Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2)CompletedNCT00998634Phase 2
34Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph DiseaseCompletedNCT02147886Phase 2
35A First in Human Study of RT001 in Patients With Friedreich's AtaxiaCompletedNCT02445794Phase 1, Phase 2
36Interferon Gamma-1b in Friedreich Ataxia (FRDA)CompletedNCT01965327Phase 2
37EPI-743 in Friedreich's Ataxia Point MutationsCompletedNCT01962363Phase 2
38Safety and Efficacy of EPI-743 in Patients With Friedreich's AtaxiaCompletedNCT01728064Phase 2
39Efficacy Study of Epoetin Alfa in Friedreich AtaxiaCompletedNCT01493973Phase 2
40A Study of Resveratrol as Treatment for Friedreich AtaxiaCompletedNCT01339884Phase 1, Phase 2
41Safety and Efficacy Study of A0001 in Subjects With Friedreich's AtaxiaCompletedNCT01035671Phase 2
42Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's AtaxiaCompletedNCT01016366Phase 2
43A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's AtaxiaCompletedNCT00897221Phase 2
44Efficacy of EGb761 in Patients Suffering From Friedreich AtaxiaCompletedNCT00824512Phase 2
45Efficacy of Epoetin Alfa in Patients With Friedreich's AtaxiaCompletedNCT00631202Phase 2
46A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's AtaxiaCompletedNCT00530127Phase 1, Phase 2
47Idebenone to Treat Friedreich's AtaxiaCompletedNCT00229632Phase 2
48Iron-Chelating Therapy and Friedreich AtaxiaCompletedNCT00224640Phase 1, Phase 2
49Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar AtaxiaRecruitingNCT02540655Phase 2
50RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIeRecruitingNCT02255435Phase 2

Search NIH Clinical Center for Cerebellar Degeneration

Genetic Tests for Cerebellar Degeneration

About this section

Anatomical Context for Cerebellar Degeneration

About this section

MalaCards organs/tissues related to Cerebellar Degeneration:

36
Brain, Cortex, Spinal cord, Cerebellum, Lung, Breast, Medulla oblongata

Publications for Cerebellar Degeneration

About this section

Articles related to Cerebellar Degeneration:

(show top 50)    (show all 552)
idTitleAuthorsYear
1
Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. (27957508)
2017
2
Anti-Yo positive paraneoplastic cerebellar degeneration in the setting of cholangiocarcinoma. (27816258)
2017
3
CAG repeat length does not associate with the rate of cerebellar degeneration in spinocerebellar ataxia type 3. (27942452)
2017
4
Structural cerebellar correlates of cognitive and motor dysfunctions in cerebellar degeneration. (28043955)
2017
5
Paraneoplastic Cerebellar Degeneration Associated with Pelvic Liposarcoma: A Rare Case Report. (28092914)
2017
6
An uncommon manifestation of paraneoplastic cerebellar degeneration in a patient with high grade urothelial, carcinoma with squamous differentiation: A case report and literature review. (27209351)
2016
7
Multiple System Atrophy Mistaken for Autoimmune Cerebellar Degeneration. (27107926)
2016
8
Anti-Ri antibody-mediated paraneoplastic cerebellar degeneration: A rare, treatable yet poorly recognized entity. (27625249)
2016
9
Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review. (27606347)
2016
10
Restoring Balance: Paraneoplastic Cerebellar Degeneration. (27816447)
2016
11
A case of slowly progressive anti-Yo-associated paraneoplastic cerebellar degeneration successfully treated with antitumor and immunotherapy. (27356731)
2016
12
Voltage-gated calcium channel autoimmune cerebellar degeneration: Case and study of cytotoxicity. (27088118)
2016
13
Secondary orthostatic tremor in the setting of cerebellar degeneration. (26765757)
2016
14
Paraneoplastic Cerebellar Degeneration-A Rare Presentation of Ovarian Malignancy. (27803545)
2016
15
Progressive cerebellar degeneration revealing Primary SjAPgren Syndrome: a case report. (27777786)
2016
16
Paraneoplastic cerebellar degeneration as a marker of endometrial cancer recurrence. (27194676)
2016
17
Paraneoplastic cerebellar degeneration and endometrial cancer: a rare occurrence. (27020505)
2016
18
Smaller Absolute Quantities but Greater Relative Densities of Microvessels Are Associated with Cerebellar Degeneration in Lurcher Mice. (27147979)
2016
19
Genetic and pharmacological evidence implicates cathepsins in Niemann-Pick C cerebellar degeneration. (26908626)
2016
20
Population-based study of alcoholic cerebellar degeneration: The Atahualpa Project. (27423619)
2016
21
Hodgkin's lymphoma associated with paraneoplastic cerebellar degeneration in children: a case report and review of the literature. (27796550)
2016
22
Voltage-Gated P/Q-Type Calcium Channel Antibodies Associated With Cerebellar Degeneration. (27436538)
2016
23
Years of Drinking but Not the Amount of Alcohol Intake Contribute to the Association Between Alcoholic Cerebellar Degeneration and Worse Cognitive Performance. A Population-Based Study. (27696290)
2016
24
Alcohol-related cerebellar degeneration: not all down to toxicity? (27729985)
2016
25
Paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenia in a patient with Merkel cell carcinoma and voltage-gated calcium channel antibodies. (28006860)
2016
26
Autoimmune neurological syndromes associated limbic encephalitis and paraneoplastic cerebellar degeneration. (27592059)
2016
27
Membranous nephropathy and cerebellar degeneration with anti-GAD antibodies in type 2 diabetes mellitus. (25753172)
2015
28
Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration. (25745634)
2015
29
Ageing shows a pattern of cerebellar degeneration analogous, but not equal, to that in patients suffering from cerebellar degenerative disease. (25896930)
2015
30
Anti-yo antibody uptake and interaction with its intracellular target antigen causes purkinje cell death in rat cerebellar slice cultures: a possible mechanism for paraneoplastic cerebellar degeneration in humans with gynecological or breast cancers. (25885452)
2015
31
Ataxin-3, DNA damage repair, and SCA3 cerebellar degeneration: on the path to parsimony? (25633989)
2015
32
Early-stage Alcoholic Cerebellar Degeneration: Diagnostic Imaging Clues. (26848494)
2015
33
Dystonia and cerebellar degeneration in the leaner mouse mutant. (25791619)
2015
34
Paraneoplastic cerebellar degeneration and dermatomyositis as first manifestations of underlying breast malignancy: a report of two cases and a brief review of the subject. (26366356)
2015
35
JC virus granule cell neuronopathy: A cause of infectious cerebellar degeneration. (26003226)
2015
36
Paraneoplastic cerebellar degeneration associated with small cell neuroendocrine mediastinal carcinoma. (26026691)
2015
37
Rapid Eye Movement-Sleep Behavior Disorder in Paraneoplastic Cerebellar Degeneration: Improvement with Immunotherapy. (26414894)
2015
38
The Effect of Cerebellar Degeneration on Human Sensori-motor Plasticity. (26140957)
2015
39
Modulation of error-sensitivity during a prism adaptation task in people with cerebellar degeneration. (26311179)
2015
40
Gaze holding deficits discriminate early from late onset cerebellar degeneration. (25980905)
2015
41
Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer. (26694863)
2015
42
Paraneoplastic cerebellar degeneration in a patient with ovarian cancer. (26166348)
2015
43
Rapid Onset of Motor Deficits in a Mouse Model of Spinocerebellar Ataxia Type 6 Precedes Late Cerebellar Degeneration. (26730403)
2015
44
Deletion of Inpp5a causes ataxia and cerebellar degeneration in mice. (26051944)
2015
45
Paraneoplastic cerebellar degeneration as an early sign of classical Hodgkin lymphoma. (26542148)
2015
46
Plasticity-related gene 5: A novel surface autoantigen in paraneoplastic cerebellar degeneration. (26445730)
2015
47
Diagnosis of Dual Malignancy by 18F-FDG-PET/CT in the setting of Paraneoplastic Cerebellar Degeneration. (26271804)
2015
48
Cerebellar Degeneration as a Rare Paraneoplastic Syndrome in a Child With Hodgkin Lymphoma. (26599987)
2015
49
Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease. (26048156)
2015
50
Paraneoplastic cerebellar degeneration with anti-CV2/CRMP5 antibodies and prostate adenocarcinoma. (25686614)
2015

Variations for Cerebellar Degeneration

About this section

Expression for genes affiliated with Cerebellar Degeneration

About this section
Search GEO for disease gene expression data for Cerebellar Degeneration.

Pathways for genes affiliated with Cerebellar Degeneration

About this section

GO Terms for genes affiliated with Cerebellar Degeneration

About this section

Sources for Cerebellar Degeneration

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet